AU2002352974A1 - Formulations for oral administration of cromolyn sodium - Google Patents

Formulations for oral administration of cromolyn sodium

Info

Publication number
AU2002352974A1
AU2002352974A1 AU2002352974A AU2002352974A AU2002352974A1 AU 2002352974 A1 AU2002352974 A1 AU 2002352974A1 AU 2002352974 A AU2002352974 A AU 2002352974A AU 2002352974 A AU2002352974 A AU 2002352974A AU 2002352974 A1 AU2002352974 A1 AU 2002352974A1
Authority
AU
Australia
Prior art keywords
formulations
oral administration
cromolyn sodium
cromolyn
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002352974A
Other languages
English (en)
Other versions
AU2002352974A8 (en
Inventor
Richat Abbas
Ehud Arbit
Michael Goldberg
Donald J. Sarubbi
Vivian Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emisphere Technologies Inc
Original Assignee
Emisphere Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emisphere Technologies Inc filed Critical Emisphere Technologies Inc
Publication of AU2002352974A1 publication Critical patent/AU2002352974A1/en
Publication of AU2002352974A8 publication Critical patent/AU2002352974A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2002352974A 2001-11-29 2002-11-29 Formulations for oral administration of cromolyn sodium Abandoned AU2002352974A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US33439501P 2001-11-29 2001-11-29
US60/334,395 2001-11-29
US38491602P 2002-05-24 2002-05-24
US60/384,916 2002-05-24
PCT/US2002/038247 WO2003045331A2 (en) 2001-11-29 2002-11-29 Formulations for oral administration of cromolyn sodium

Publications (2)

Publication Number Publication Date
AU2002352974A1 true AU2002352974A1 (en) 2003-06-10
AU2002352974A8 AU2002352974A8 (en) 2003-06-10

Family

ID=26989179

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002352974A Abandoned AU2002352974A1 (en) 2001-11-29 2002-11-29 Formulations for oral administration of cromolyn sodium

Country Status (6)

Country Link
US (2) US20040259952A1 (enExample)
EP (1) EP1461031B1 (enExample)
JP (1) JP5196701B2 (enExample)
AU (1) AU2002352974A1 (enExample)
CA (1) CA2466863A1 (enExample)
WO (1) WO2003045331A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
CA2563335A1 (en) 2004-04-16 2005-12-08 Emisphere Technologies, Inc. 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
CA2565188C (en) * 2004-05-14 2014-03-04 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
NZ588373A (en) 2004-05-19 2012-01-12 Emisphere Tech Inc Topical cromolyn formulations
EP1750718B1 (en) 2004-05-19 2014-08-13 Emisphere Technologies, Inc. Acyclovir formulations
CA2591515C (en) 2004-12-29 2010-06-22 Emisphere Technologies, Inc. Pharmaceutical formulations of gallium salts
US8110547B2 (en) 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
JP4558045B2 (ja) * 2005-11-01 2010-10-06 株式会社リバース・プロテオミクス研究所 アレルギー疾患の治療に有用な化合物をスクリーニングする方法
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
CA2656019C (en) 2006-06-28 2016-09-13 Emisphere Technologies, Inc. Gallium nitrate formulations
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
WO2009045291A2 (en) * 2007-09-28 2009-04-09 The Brigham And Women's Hospital, Inc. Mast cell stabilizers in the treatment of obesity
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CA2751125C (en) * 2009-01-29 2017-06-20 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20110039930A1 (en) 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CA2832811A1 (en) 2011-04-12 2012-10-18 Novo Nordisk A/S Double-acylated glp-1 derivatives
US8843456B2 (en) 2011-12-06 2014-09-23 International Business Machines Corporation Database table compression
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
HUE064694T2 (hu) 2012-03-22 2024-04-28 Novo Nordisk As Továbbítószert tartalmazó készítmények és elõállításuk
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
EP2978441A4 (en) * 2013-03-27 2017-02-08 ScPharmaceuticals Inc. Combination therapy for subcutaneous administration of glycopeptide antibiotics
AU2014261336B2 (en) 2013-05-02 2019-02-28 Novo Nordisk A/S Oral dosing of GLP-1 compounds
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2015070116A2 (en) * 2013-11-11 2015-05-14 Harish Ziv M D Formulations and methods for prevention and treatment of oral allergy syndrome
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10588974B2 (en) 2016-04-22 2020-03-17 Receptor Holdings, Inc. Fast-acting plant-based medicinal compounds and nutritional supplements
NZ751668A (en) 2016-08-17 2022-07-29 Entera Bio Ltd Formulations for oral administration of active agents
AU2017321495A1 (en) 2016-08-31 2019-03-21 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017339366A1 (en) 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
JP7281815B2 (ja) * 2017-01-03 2023-05-26 レセプター・ホールディングス・インコーポレイテッド 医薬化合物及び栄養補給剤
MX2020000577A (es) 2017-07-20 2020-09-10 Aztherapies Inc Formulaciones en polvo de cromolina sodica e ibuprofeno.
WO2019112552A1 (en) * 2017-12-04 2019-06-13 Aztherapies, Inc Cromolyn compositions and methods thereof
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
CA3105392A1 (en) 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
UA122811C2 (uk) * 2018-08-10 2021-01-06 Наталія Миколаївна Тихонівська Фармацевтична композиція
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
US12303487B2 (en) 2018-11-19 2025-05-20 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US11986492B2 (en) * 2022-09-21 2024-05-21 Ashley Wolchina Allison Oral supplement for preventing colic in horses
CN116509836A (zh) * 2023-03-23 2023-08-01 中山万汉制药有限公司 色甘酸钠－季铵盐复合物及其制备方法与用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6281380A (ja) * 1985-10-04 1987-04-14 Kyoto Yakuhin Kogyo Kk クロモグリク酸誘導体、その製造法および抗アレルギ−剤
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5447728A (en) 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
JPH06281380A (ja) 1993-03-26 1994-10-07 Hisaka Works Ltd プレート式熱交換器用ガスケット
DE69434418T2 (de) 1993-04-22 2005-12-22 Emisphere Technologies, Inc. Orale Dareichungsform
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
WO1998008504A1 (en) * 1996-08-30 1998-03-05 Kyoto Pharmaceutical Industries, Ltd. Remedies for allergic dermatitis
EP0993831B1 (en) 1997-02-07 2008-01-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5888529A (en) * 1997-03-28 1999-03-30 The Regents Of The University Of California Ileus treatment method
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5952353A (en) * 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
AU2117399A (en) * 1998-01-20 1999-08-02 Applied Analytical Industries, Inc. Oral liquid compositions
JP4675481B2 (ja) * 1998-07-27 2011-04-20 エミスフェアー・テクノロジーズ・インク 活性剤の肺性デリバリー
WO2000007979A2 (en) * 1998-08-07 2000-02-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
EP1163209A4 (en) * 1999-02-26 2004-12-29 Emisphere Tech Inc COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE INGREDIENTS
DE60017888T2 (de) * 1999-04-05 2006-01-19 Emisphere Technologies, Inc. Dinatrium-salze, monohydrate und ethanol-solvate
WO2001032130A2 (en) * 1999-11-05 2001-05-10 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
JP4850379B2 (ja) * 1999-12-16 2012-01-11 エミスフェアー・テクノロジーズ・インク 活性剤を輸送するための化合物及び組成物
CA2292902C (en) * 1999-12-24 2012-12-18 Alain Cadieux Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases
JP4879433B2 (ja) * 2000-01-13 2012-02-22 エミスフェアー・テクノロジーズ・インク 活性剤を送達するための化合物および組成物
US6225356B1 (en) * 2000-01-20 2001-05-01 Jones, Iii Tudor Cromolyn sodium containing composition and method of treatment for vilvar vestibulitis interstitial cystitis vukvar vaginitis and vaginitis dynea
US20020028193A1 (en) * 2000-02-15 2002-03-07 Cornett Lawrence E. Recombinant beta2-adrenergic receptor delivery and use in treating airway and vascular diseases
EP1299348B1 (en) * 2000-06-29 2008-04-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1313441C (zh) * 2000-09-06 2007-05-02 艾米斯菲尔技术有限公司 用于递送活性剂的氰基苯氧基羧酸化合物及其组合物

Also Published As

Publication number Publication date
EP1461031B1 (en) 2016-06-29
US20040259952A1 (en) 2004-12-23
WO2003045331A3 (en) 2003-08-14
WO2003045331A2 (en) 2003-06-05
AU2002352974A8 (en) 2003-06-10
JP5196701B2 (ja) 2013-05-15
EP1461031A2 (en) 2004-09-29
CA2466863A1 (en) 2003-06-05
EP1461031A4 (en) 2011-06-22
US20080194676A1 (en) 2008-08-14
US8513300B2 (en) 2013-08-20
JP2005510535A (ja) 2005-04-21

Similar Documents

Publication Publication Date Title
AU2002352974A1 (en) Formulations for oral administration of cromolyn sodium
PL356358A1 (en) Solid dosage form of someticone for oral administration
AU762322C (en) Novel galenic formulations of meloxicam for oral administration
AU2003229555A1 (en) Oral administration form for difficulty soluble basic active ingredients which are applied orally
AU2001231000A1 (en) Dry powder formulations of antihistamine for nasal administration
EP1424994A4 (en) PREPARATION OF A SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION
HUP0400850A3 (en) Oral pharmaceutical compositions
AU2001297631A1 (en) Novel formulations of carvedilol
AU2001284444A1 (en) Preparations for oral administration
GB0121715D0 (en) Pharmaceutical formulations
GB0203527D0 (en) Pharmaceutical formulations
AU2003249105A1 (en) Processes for the preparation of oral dosage formulations of modafinil
GB0120701D0 (en) Pharmaceutical formulations
GB0202900D0 (en) Novel formulations of drugs
GB0103638D0 (en) Pharmaceutical formulations
IL166337A0 (en) Oral administration of calctionin
GB0105560D0 (en) Pharmaceutical formulations
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives
AU2003295846A1 (en) Pharmaceutical formulations of celcoxib
AU2003284786A1 (en) Microemulsion composition for oral administration of biphenyldimethyldicarboxylate
AU2003263480A1 (en) Oral pharmaceutical compositions of fenofibrate having high bioavailability
AU2003247001A1 (en) Processes for the preparation of oral dosage formulations of modafinil
AU2001239349A1 (en) Oral pharmaceutical compositions containing n-sulphonylindoline derivatives
GB0124455D0 (en) Pharmaceutical formulations
AU2002339720A1 (en) Improved pharmaceutical dental formulations

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase